Cancer-related LncRNA Microarray Service
As a leading service provider in the field of microarray, CD Genomics is committed to designing and developing various useful microarray tools for scientific research and non-clinical research. Our microarray test platform provides a full range of analysis services on the relationship between microarray-based cancer signal pathway regulation and lncRNA to help our global customers conduct relevant research and reduce research costs. With our time-tested capabilities and expertise, we are confident to provide you with quality services to escort your research.
Cancer-related LncRNA Expression Profiling
The cause of cancer is the genetic changes of specific genes that give cells the ability to divide and grow uncontrollably. There are usually many processes and signal transduction pathways involved and complex relationships. The huge differences in the genes and pathways that are altered in different tumor types and individual tumor samples make it difficult to fully understand the genes and pathways that are altered in all cancer types. Some important signal transduction pathways have been identified as frequently changing in cancer, which is essential for identifying potential therapeutic targets. Most cancers occur in epithelial cells and manifest as cancers in organs such as the lung, skin, breast, liver, and pancreas. The sarcoma originates from mesenchymal tissue and exists in fibroblasts, muscle cells, adipocytes, and osteoblasts. Non-epithelial tumors can also develop in cells of the nervous system (such as glioma, neuroblastoma, and medulloblastoma) and hematopoietic tissues (leukemia and lymphoma). The abnormal regulation of cell signal transduction in different types of tumors plays different roles. The role of long non-coding RNA (lncRNA) in different types of cancer is different, but it is accompanied by some important signal pathways. Microarrays are very helpful for the rapid detection of these fragments.
Fig 1. LncRNAs in Cancer Phenotypes. (Schmitt A M, et al. 2016)
Service Process
Genetic changes in signal transduction pathways that control cell cycle progression, apoptosis, and cell growth are common features of cancer, but the degree, mechanism, and coexistence of these pathways are different among tumors and tumor types. Based on the reported data and public databases, we designed a microarray tool for rapid analysis of lncRNA related to cancer-related signal pathways. This tool can be used to analyze the role of lncRNA in specific cancers. It aims to analyze the cancer-specific lncRNA of the focused pathway and the gene targets in the signal pathway together to clarify its potential regulatory mechanism and gain insight into specific biological pathways or diseases. Our tumor-specific lncRNA microarray array can be used to analyze lncRNA in important signal pathways of tumorigenesis, including cell cycle (proliferation and apoptosis), signal transduction. Microarray designs include single tumors or combined targets. The probe set includes lncRNA and target oligonucleotide probes that may affect the coding gene. Each probe contains more than 2 repeats, which ensures the high sensitivity of the product. We provide one-stop testing and analysis services, from sample pretreatment, microarray testing to data collection and analysis, you can choose us with confidence.
Fig 2. Cancer-specific lncRNA microarray service process.
Our Benefits
- Carry out unique design for lncRNA involved in cancer-related signal pathways to improve detection efficiency;
- A complete experimental platform, an experienced team of experimentalists;
- Strong bioinformatics team, high-quality data analysis.
CD Genomics provides high-quality microarray tools and testing services for the research of signal pathway-related lncRNA in cancer. We have a large and well-equipped team of scientists who are committed to cooperating with researchers from all over the world. If you have relevant testing requirements, please contact us for more detailed information.
References
- Schmitt A M, Chang H Y. Long noncoding RNAs in cancer pathways[J]. Cancer cell, 2016, 29(4): 452-463.
- Sever R, Brugge J S. Signal transduction in cancer[J]. Cold Spring Harbor perspectives in medicine, 2015, 5(4): a006098.
- Kessler T, Hache H, Wierling C. Integrative analysis of cancer-related signaling pathways[J]. Frontiers in Physiology, 2013, 4: 124.
- Sun W, Shi Y, Wang Z, et al. Interaction of long-chain non-coding RNAs and important signaling pathways on human cancers[J]. International journal of oncology, 2018, 53(6): 2343-2355.
Our products and services are for research purposes ONLY. We do not perform any private testing services that are not for laboratory use.
